Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer

Autor: Joanna Budna-Tukan, Catherine Alix-Panabières, Michał Nowicki, Wojciech A Cieślikowski, Agnieszka Ida, Andrzej Antczak, Monika Świerczewska, Agnieszka Jankowiak, Maciej Zabel, Michał Hrab, Martine Mazel, Klaus Pantel, Piotr Milecki
Přispěvatelé: Poznan University of Medical Sciences [Poland] (PUMS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), University of Wrocław [Poland] (UWr), University of Zielona Góra
Rok vydání: 2020
Předmět:
Zdroj: Cancers
Volume 12
Issue 1
Cancers, Vol 12, Iss 1, p 160 (2020)
Cancers, MDPI, 2020, 12 (1), pp.160. ⟨10.3390/cancers12010160⟩
ISSN: 2072-6694
Popis: The aim of this study was to investigate whether the enumeration of circulating tumor cells (CTCs) in blood can differentiate between true localized and metastatic prostate cancer. A cross-sectional study of 104 prostate cancer patients with newly diagnosed high-risk prostate cancer was conducted. In total, 19 patients presented metastatic disease and 85 were diagnosed with localized disease. Analyses included intergroup comparison of CTC counts, determined using the CellSearch®
system, EPISPOT assay and GILUPI CellCollector®
and ROC analysis verifying the accuracy of CTC count as a maker of disseminated prostate cancer. The vast majority (94.7%) of patients with advanced-stage cancer tested positively for CTCs in at least one of the assays. However, significantly higher CTC counts were determined with the CellSearch®
system compared to EPISPOT assay and GILUPI CellCollector®
Identification of &ge
4 CTCs with the CellSearch®
system was the most accurate predictor of metastatic disease (sensitivity 0.500
specificity 0.900
AUC (95% CI) 0.760 (0.613&ndash
0.908). Furthermore, we tried to create a model to enhance the specificity and sensitivity of metastatic prediction with CTC counts by incorporating patient&rsquo
s clinical data, including PSA serum levels, Gleason score and clinical stage. The composite biomarker panel achieved the following performance: sensitivity, 0.611
specificity, 0.971
AUC (95% CI), 0.901 (0.810&ndash
0.993). Thus, although the sensitivity of CTC detection needs to be further increased, our findings suggest that high CTC counts might contribute to the identification of high-risk prostate cancer patients with occult metastases at the time of diagnosis.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje